International Regulatory Overview 2009 Rev Linkedln

International Regulatory Overview
Canada - USA - Europe - Australia - Asia

By : Roger Leclerc - Speaker
Title : Senior Director, Regulatory Affairs & Export
Date: March 17, 2009

March 17, 2009 International Regulatory Overview 1

Accept New Challenges


Overview

Medical Devices Regulatory Overview - Country

3. Canada - Therapeutic Products Directorate (TPD)
4. United States - Food & Drug Administration (FDA)
5. Europe - Competent Authority (TUV, BSI) - Member
States
6. Australia - Therapeutic Goods Administration (TGA)
7. Asia - Ministry of Health (MHLW - SFDA)


Canada’s Challenges

 Regulatory & Program Modernization of the Food &
Drug Act
 Enforcement Powers - Consequences Non-Compliance
 Life Cycle of a Medical Device - Develop Investigational
Testing Inspection Strategy & Program
 Proactive - Surveillance of Safety & Effectiveness &
Post Market Activities - Inspections
 Experienced Resource Planning - Knowledge Transfer
 Adequate Funding - Meet Requirements
 Admin. Governance - Performance Standards
 International Transparency & Stakeholder framework
 Performance Measurement Framework for Success &
Continuous Improvement - Regulatory Process


United States - Challenges

 Disputes Concerning Payment or Refund of Medical
Device User Fees
 User Fees & Refunds for Premarket Notification
Submissions
 Guidance on Postmarket Issues
 Device Specific Guidance's
 Standards Related Guidance's
 Cross-Cutting & Process Guidance
 CDRH Enforcement Discretion
 510(k) Paradigm
 Summary Technical Documentation for Demonstrating
Conformity to the Essential Principles of Safety &
Performance


Europe’s - Challenges

 Medical Devices Directive (90/385/EEC and 93/42/EEC2)
 Risk-Based Classification
 Non-Regulated Medical Devices
 Implantable / Invasive Devices for Aesthetic Purposes
 Revision of the "New Approach"
 Essential Requirements
 National Specific Requirements
 Notified Bodies
 Info exchange Notified Bodies & Competent Authorities
 Cooperation between Competent Authorities
 Safeguard clause & withdrawal of certificate
 Vigilance
 Market Surveillance


Australia’s - Challenges

 Regulation of custom made medical devices
 Third Party Conformity Assessment Bodies for Medical
Devices Supplied in Australia
 Technical Review of the Code of Practice for the
Tamper-Evident Packaging (TEP)
 General requirements for labels for medicines
 Remedial actions for medical devices
 Review of TGA actions
 Conformity assessment overview
 Conformity assessment for manufacturers


Asia’s - Challenges

 Japan Revises GCP for Medical Devices & Drugs
 Indonesia Orders Foreign Drug makers to Manufacture In-
Country
 Diabetes Increasing Rapidly in China - Glucose Monitors
 India Proposes Quality Certification for Medical Devices
 Japan Works to Cut Drug and Device Lag
 Taiwan To Create Food & Drug Administration For Food &
Drug Safety
 Singapore Tightens Regulation on Medical Device
Advertising
 India Cracks Down on Fake Drugs


Health Canada


Medical Devices Strategic Objective - 2012

1. Regulatory & Program Modernization

 Strengthen safety oversight - Adopt of life cycle
approaches - Risk Management Framework
 Increase & Strengthen Regulatory Tools and
Abilities - Learn & Share - Jurisdictions
 Identify shared activities with other jurisdictions
 Develop programs to provide consequences for
Non-compliance with regulations
 Amend Investigational Testing Regulations
 Investigational Testing Inspection Strategy &
Program - Compliance to GCP - Reporting to HC
 Strengthen Post Market Activities, Surveillance &
Safety & Effectiveness monitoring - Risk basis



2. Human Resources

 Knowledge transfer - talented staff
 HR Planning - skills, experience - future
 Training of staff due to science & technology
 Develop a culture of cross training
 Working together - Three different directorates
 Therapeutic Product Directorate (TPD), Health
Products and Food Branch Inspectorate (HPFBI),
Marketed Health Products Directorate (MHPD)



3. Adequate Funding

 Cost recovery – Charging framework to cover the
regulation, licensing & post market surveillance of
health products & medical devices
 Branch - Comprehensive review of programs &
resources to ensure adequate funding to deliver
mandated activities
 Identify gaps in its activities - for emerging issues &
meet strategies - Cabinet & Treasury Board to finance
programs not funded by Recovery Cost



4. Governance & Business Transformation

 Manage better - current Structure - Collaboration of
the Directorate & Inspectorate to discuss Medical
Devices Issues i.e. funding for programs
 Therapeutic Products Directorate (TPD), Marketed
Health Products Directorate (MHPD), Health Products
and Food Branch Inspectorate (HPFBI))
 Review of Structural Options for Longer Term
- Review organizational structures to handle device
issues as the industry grows, Develop service
standards - i.e. MDEL issuance
- Develop Performance Measurements for all aspects
of the Medical Devices Program - outlining
sustainable activities



5. Work in Partnerships, Effective, Transparent
Communication

 Focus Approach to International Cooperation
- Global Harmonization Task Force (GHTF) - Share
activities with Food Drug Administration (FDA),
Therapeutic Goods Administration (TGA)
- Harmonization of Regulatory System - Medical
Devices - provide expertise - International & National
Standards



 Strong & Positive Partnerships with Stakeholders
- Develop joint activities - organization - associations
- Canadian Border Services Agency - Address Non-compliant
devices entering Canada
- Engage stakeholders and provincial regulatory authorities to
discuss and plan end user training - high risk devices

 Improve Communications with Stakeholders
- Identify & improve timeless of communications
- Registration & disclosure of Clinical Trial Information
- Rely on - Expert Advisory Committee - Mechanisms improve
stakeholder Communications


Learn New Things


Regulatory Issues & Outcome - 2008 - 2009

1. Standards Recognition

 New list of Recognized Standards Updated Feb 2008

 Proposal to Remove 2nd Edition Dec. 15, 2008 & Move
forward with Third Edition of IEC 60601-1

 Input from the Medical Devices Companies is
forthcoming to discuss appropriate way to move
forward with 3 rd edition of 60601-1 & its associated
standards



2. Special Access Program

 Advisory Panel - Provide Options - Posted
 Review documentation by Health Canada, listen to
presentations at a public forum
 Make propose recommendations and various options
for modernizing the Special Access Program
 A Report will be prepared and will be posted to the HC
website.
 Industry - invited to provide input



3. Significant Changes

 MDB increasing significant changes following recalls -
safety & effectiveness
 Industry is stating other jurisdiction is non significant
 MDB has instructed industry to discontinue sale of the
device
 MDB will expedite significant change amendments
related to a recall
 Industry is stating - Corrective & Preventative Actions
part of a recall must be clear and harmonized with other
jurisdictions
 MDB has invited industry to provide input - before
revision of the guidance document



4. Sale of Unlicensed Devices

 Industry - Hospitals, Buying Groups, Dealers, receiving
quotes - new devices coming to Canada & unlicensed
 MDB - A purchase process - based on promotion could
be viewed as an activity vs. regulations
 HC- No Intention to sell a device
 Not used on an individual
 Label the device not licensed in accordance with
Canadian Law
 Return device out of Canada if at a tradeshow
 The device to be under direct control of the company at
all times



5. Device Establishment Licence

 Section 44(1) No person shall import or sell a medical
device unless - Establishment License
 Importers wish to sell product - new manufacturer or
new class from current manufacturer - applicant cannot
import or sell these products until receipt of amended
MDEL
 Currently the one form - Requires 15 day notification -
for administrative changes on the current MDEL i.e.
corporate name changes, contact person



6. New Food & Drug Act Liaison Office (FDALO)

 Aimed at preventing & resolving disputes with
Stakeholders
 Mandate - Receive complaints, concerns or inquires -
alleged acts, omissions, matters related to Food &
Drugs Act, listen, offer options, facilitate, investigate
 FDALO has no statutory powers to investigate- not give
legal advice - change policies -
 Ms Serena Siqueira Director of the Food and Drugs Act
Liaison Office - Handle concerns from manufacturers -
license delays - lack of consistency



7. Modernization of the Food and Drug Act

 Minister Clement Introduced Bill C-51 - April 2008
 Proposes the modernization of how HC regulates
therapeutic products
 Supports the implementation of a life cycle approach
(Progressive Licensing) to the regulations of medical
devices & pharmaceuticals
 Industry requested that the term Recall be explored to
 Progressive Licensing -
www.healthcanada.gc.ca/progressive_licensing
 Bill C-51 - http://www.parl.gc.ca/legisinfo/index.asp?
Language=E&Session=15&query=5420&List=toc


Conclusion

Thank you

Medical Devices & Biosciences Int’l (MDBIO Int’l)
Website WWW.Mdbioregulatory.ca


Be Curious & Show Some Initiative


International Regulatory Overview 2009 Rev Linkedln

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (8)

Similar to International Regulatory Overview 2009 Rev Linkedln

Similar to International Regulatory Overview 2009 Rev Linkedln (20)

Recently uploaded

Recently uploaded (20)

International Regulatory Overview 2009 Rev Linkedln